Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Offer is closed

<< Previous

Bullboard Posts

Next >>

Comment by colts123on Dec 21, 2021 11:50am

189 Views

Post# 34250732

RE:RE:RE:Offer is closed

Pretty sad when the market tells what they think of this POS. They were initially looking to raise $13m, then reduced to $6.1m now they have to settle for $2.1 million, with a burn rate of 1.5m per month. what will they do after January 2022 .
Question, if they were so confident for approval from Heath Canada why didn't they wait until after the approval to do the public offering . Even if they did get the Health Canada approval it would only increase 20cents/share at best (my opinion). I am betting we will see 2 cents/share . To think they were pumping this stock to $3, $5 $10 and $20 a share this summer

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide